Application of timosaponin I in preparation of medicine for resisting human ovarian cancer

A technology of timosaponin and ovarian cancer, which is applied in the application field of timosaponin I in the preparation of anti-human ovarian cancer drugs, can solve the problems that the function and mechanism of action have yet to be studied, and timosaponin I has not been discovered, and has reached a huge The effect of medicinal potential

Active Publication Date: 2021-10-19
NANJING MEDICAL UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Anemarrhenasaponin I (Anemarrhenasaponin I, An-I) is a compound isolated from the rhizome of Zhimu. Studies have shown that it is a potential 5-lipoxygenase (5-LOX) and cyclooxygenase- 2 (COX-2) dual-targeted inhibitors, but many fun

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of timosaponin I in preparation of medicine for resisting human ovarian cancer
  • Application of timosaponin I in preparation of medicine for resisting human ovarian cancer
  • Application of timosaponin I in preparation of medicine for resisting human ovarian cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Western blotting was used to determine the effects of timosaponin I and SHH pathway inhibitor GANT61 on the expression of SKOV3-related proteins in human ovarian cancer cells.

[0025] 1. Experimental materials:

[0026] 1) Human ovarian cancer cell line SKOV3 (ATCC, USA);

[0027] 2) McCoy's5A incomplete culture medium (KGI, China);

[0028] 3) DMEM high glucose medium powder, GlutaMaxTM glutamine additive, sodium pyruvate solution and 0.25% EDTA-trypsin (Gibco company, the United States);

[0029] 4) Fetal bovine serum FBS (Wisent company, Canada);

[0030] 5) Penicillin-streptomycin-neomycin mixed antibiotics PSN and BCA protein detection kit (Thermo Fisher company, the United States);

[0031] 6) Rabbit anti-Gli1 polyclonal antibody (CST company, USA);

[0032] 7) rabbit anti-Sufu polyclonal antibody (Abcam company, the United States);

[0033] 8) rabbit anti-GAPDH polyclonal antibody (Santa Crutz Company, USA);

[0034] 9) horseradish peroxidase-labeled goat ...

Embodiment 2

[0048] Real-Time PCR was used to determine the effects of timosaponin I and SHH pathway inhibitor GANT61 on the expression of SKOV3-related mRNA in human ovarian cancer cells.

[0049] 1. Experimental materials:

[0050] 1) Human ovarian cancer cell line SKOV3 (ATCC, USA);

[0051] 2) McCoy's5A incomplete culture medium (KGI, China);

[0052] 3) DMEM high glucose medium powder, GlutaMaxTM glutamine additive, sodium pyruvate solution and 0.25% EDTA-trypsin (Gibco company, the United States);

[0053] 4) Fetal bovine serum FBS (Wisent company, Canada);

[0054] 5) Penicillin-Streptomycin-Neomycin Mixed Antibiotic PSN (Thermo Fisher Company, USA);

[0055] 6) TRIzol reagent (TaKaRa company, Japan);

[0056] 7) HiScriptⅡQ-RT SuperMix for qPCR (gDNA wiper) reverse transcription kit, AceQ qPCRSYBR Green Master Mix fluorescent quantitative PCR kit (Novazyme, China);

[0057] 8) GANT61 powder (Selleck Company, USA) was dissolved in ethanol with a concentration of 10 mM, and dilut...

Embodiment 3

[0075] Effects of timosaponin I and SHH pathway inhibitor GANT61 on proliferation of human ovarian cancer cell SKOV3 detected by EdU proliferation assay

[0076] 1. Experimental materials:

[0077] 1) Human ovarian cancer cell line SKOV3 (ATCC, USA);

[0078] 2) McCoy's5A incomplete culture medium (KGI, China);

[0079] 3) DMEM high glucose medium powder, GlutaMaxTM glutamine additive, sodium pyruvate solution and 0.25% EDTA-trypsin (Gibco company, the United States);

[0080] 4) Fetal bovine serum FBS (Wisent company, Canada);

[0081] 5) Penicillin-Streptomycin-Neomycin Mixed Antibiotic PSN (Thermo Fisher Company, USA);

[0082] 6) EdU cell proliferation detection kit (Ribo Biotechnology, China);

[0083] 7) GANT61 powder (Selleck Company, USA) was dissolved in ethanol with a concentration of 10 mM, diluted with medium for experiment use;

[0084] 8) Timosaponin powder (Nanjing University of Traditional Chinese Medicine, China) was dissolved in DMSO at a concentration o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of timosaponin I in preparation of anti-human ovarian cancer drugs, and belongs to the technical field of new medical application of the timosaponin I. The molecular formula of the timosaponin I is C39H66O14, and the chemical structural formula of the timosaponin I is shown in the specification. The timosaponin I can effectively inhibit expression of mRNA of SHH signal channel related target genes and protein GLI1 and SUFU in human ovarian cancer cells SKOV3; the timosaponin I can effectively inhibit proliferation, epithelial-mesenchymal transition (EMT), migration and invasion of SKOV3 cells, and it is indicated that the timosaponin I is expected to be developed into an effective component of the medicine for resisting the human ovarian cancer. In addition, the medicine can be prepared into different preparation forms according to the requirements of patients, is convenient for the patients to take, and has better development and application prospects.

Description

technical field [0001] The invention belongs to the technical field of new medical applications of timosaponin I, and in particular relates to the application of timosaponin I in the preparation of anti-human ovarian cancer drugs. Background technique [0002] Ovarian cancer is the most common malignant tumor in women over the age of 40, second only to breast cancer, and the deadliest gynecological cancer. According to the 2020 survey, there are approximately 313,959 new cases of ovarian cancer and 207,252 deaths worldwide each year. Due to the relatively hidden location of the ovary and the lack of effective screening methods, the vast majority of ovarian cancers have already metastasized when diagnosed. At present, the treatment mode of ovarian cancer is mainly based on tumor reduction surgery and chemotherapy based on platinum drugs. Ovarian cancer patients often go through a cycle of surgery-chemotherapy-relapse-chemotherapy-relapse-re-chemotherapy, during which the sen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61P35/00A61P15/08A61K36/8964
CPCA61K31/7048A61P35/00A61P15/08A61K36/8964
Inventor 邓斯敏刘晨许元高彬斌张静怡俞婷婷乐珅程雁
Owner NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap